ORG – Page 4 – Talk Bio

NewAmsterdam Reports Cholesterol Drug Obicetrapib May Slow Alzheimer’s Biomarker Buildup

4 days ago talkbio0Tagged Alzheimer 's disease, Apolipoprotein E4, Biological Markers, CETP, cholesterol ester transfer protein inhibitor, NewAmsterdam Pharma, Obicetrapib, p-tau217, Phase 3

NewAmsterdam Pharma; obicetrapib; cholesterol ester transfer protein inhibitor (CETP); Alzheimer’s disease biomarkers; p-tau217; ApoE4; BROADWAY trial; Phase 3

RFK Jr. Ousts All Members of CDC’s Vaccine Advisory Panel in ‘Clean Sweep’

4 days ago talkbio0Tagged ACIP, Centers for Disease Control and Prevention (U.S.), CHARGE Syndrome, clean sweep, public trust, RFK Jr., Robert F. Kennedy Jr., vaccine advisory panel

RFK Jr.; CDC; vaccine advisory panel; Robert F. Kennedy Jr.; ACIP; clean sweep; public trust; HHS

Merck’s Enflonsia FDA Approval Spurs Sanofi to Accelerate Beyfortus Supply Ahead of 2025-26 RSV Season

5 days ago talkbio0Tagged Approved, AstraZeneca, Beyfortus, Enflonsia, Health care facility, Immunization, Infant, Merck, Respiratory syncytial virus, sanofi, supply chain, United States Food and Drug Administration

RSV; Infant immunization; Merck; Sanofi; Beyfortus; Enflonsia; FDA approval; supply chain; healthcare; AstraZeneca

Merck’s Oral PCSK9 Inhibitor Enlicitide Significantly Reduces LDL Cholesterol in Phase 3 Trials

5 days ago talkbio0Tagged Administration of prophylactic statin, cholesterol, CORALreef, CORALreef AddOn, enlicitide, HeFH, Hypercholesterolemia, Familial, Hyperlipidemia, LDL-C, Merck, Oral Therapy, PCSK9 inhibitor

Merck; PCSK9 inhibitor; enlicitide; phase 3 trials; cholesterol; LDL-C; oral therapy; hyperlipidemia; familial hypercholesterolemia; CORALreef HeFH; CORALreef AddOn; statin therapy

Federally-Funded Cancer Research at a Perilous Crossroads: Deep Cuts Threaten Progress

5 days ago talkbio0Tagged AACR, Budgets, Cancer Research, Congress (U.S. Legislature), federal, Funding, Malignant neoplasm of lung, NIH Mouse, Pancreatic carcinoma, public health policy

federal funding; cancer research; NIH budget cuts; Congress; lung cancer; pancreatic cancer; AACR; public health policy

AstraZeneca’s Calquence Combo Approved for First-Line CLL in EU

5 days ago talkbio0Tagged Amplify trial, Approved, AstraZeneca, BTK inhibitor, Calquence, Chronic Lymphocytic Leukemia, EU, First line treatment, obinutuzumab, venetoclax

AstraZeneca; Calquence; EU approval; chronic lymphocytic leukaemia; first-line treatment; venetoclax; obinutuzumab; BTK inhibitor; Amplify trial

EMA Identifies Very Rare Eye Condition as Side Effect of Semaglutide

1 week ago talkbio0Tagged Adverse effects, Blindness, Infrequent, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, NAION, Ozempic, Rybelsus, semaglutide, Wegovy

EMA; semaglutide; rare side effect; NAION; vision loss; Ozempic; Wegovy; Rybelsus

MIT’s Boltz-1 AI Model Rivals AlphaFold 3 in Biomolecular Structure Prediction

1 week ago talkbio0Tagged AlphaFold, Aortic Valve Insufficiency, Artificial Intelligence, biomolecular structure prediction, Boltz-1, Drug Discovery, MIT, open-source AI, protein folding

MIT; Boltz-1; AlphaFold 3; AI model; biomolecular structure prediction; drug discovery; protein folding; open-source AI

Otsuka’s Phase 3 IgAN Win with Sibeprenlimab Shakes Vera’s Stock

1 week ago talkbio0Tagged IGA Glomerulonephritis, Kidney Diseases, Otsuka, Priority Review, Proteinuria, Sibeprenlimab, stock drop, United States Food and Drug Administration, UPCR, vera

Otsuka; sibeprenlimab; IgA nephropathy; phase 3 trial; proteinuria reduction; Vera Therapeutics; stock drop; kidney disease; UPCR; FDA Priority Review

GSK Appoints Sanofi Veteran to Lead Vaccines R&D; Leadership Change at Bristol Myers Corporate Affairs

1 week ago talkbio0Tagged affairs, Corporate, Drug Industry, executive appointment, Gurunathan, Leadership Change, Myers, R&D, Sanjay, sanofi, SmithKline Beecham, squibb, Vaccines

GSK; Sanofi; vaccine R&D; Sanjay Gurunathan; leadership change; pharmaceutical industry; Bristol Myers Squibb; corporate affairs; executive appointment